SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BJDX reported Third Quarter 2026 results. The price and volatility reaction is pending.
BJDXearnings

Earnings reactions, page 2

Bluejay Diagnostics, Inc. (BJDX) Q3 FY2026 earnings

November 14, 2026 · SharpeIQ Research Desk

Reported results

  • As of September 30, 2026, cash and cash equivalents were $7.38 million, compared with $5.16 million at December 31, 2025.
  • Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $5.09 million.
  • Completed SYMON-II clinical study enrollment, exceeding the original target of 750 patients.
  • Preliminary baseline analysis of 777 evaluable patients identified 140 deaths within 28 days, representing approximately 18% mortality.

Guidance

  • Existing cash resources are estimated to support operations through the second quarter of 2027.
  • Plans FDA 510(k) submission for Symphony IL-6 during the first half of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →